Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics (NASDAQ: AVTX), a clinical stage biotech company specializing in immune dysregulation treatments, has announced its participation in two upcoming investor conferences in June 2025. The company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, at 7:35 am ET in New York. Additionally, management will join a panel discussion titled "Dermatology: AA, HS, PSO" at the Oppenheimer Innovators in I&I Summit on June 25, 2025, at 10am ET in New York. Webcasts and replays will be available on the company's investor relations website for at least 30 days.
Avalo Therapeutics (NASDAQ: AVTX), una società biotecnologica in fase clinica specializzata in trattamenti per la disfunzione immunitaria, ha annunciato la sua partecipazione a due prossimi conferenze per investitori nel giugno 2025. La società parteciperà a una tavola rotonda informale al Jefferies Global Healthcare Conference il 4 giugno 2025 alle 7:35 ET a New York. Inoltre, il management prenderà parte a una discussione panel intitolata "Dermatologia: AA, HS, PSO" al Oppenheimer Innovators in I&I Summit il 25 giugno 2025 alle 10:00 ET a New York. Le webcast e le registrazioni saranno disponibili sul sito web delle relazioni con gli investitori della società per almeno 30 giorni.
Avalo Therapeutics (NASDAQ: AVTX), una empresa biotecnológica en etapa clínica especializada en tratamientos para la disfunción inmunitaria, ha anunciado su participación en dos próximas conferencias para inversores en junio de 2025. La compañía participará en una charla informal en el Jefferies Global Healthcare Conference el 4 de junio de 2025 a las 7:35 am ET en Nueva York. Además, la dirección participará en un panel titulado "Dermatología: AA, HS, PSO" en el Oppenheimer Innovators in I&I Summit el 25 de junio de 2025 a las 10:00 am ET en Nueva York. Las transmisiones en vivo y las repeticiones estarán disponibles en el sitio web de relaciones con inversores de la compañía durante al menos 30 días.
Avalo Therapeutics (NASDAQ: AVTX)는 면역 기능 이상 치료를 전문으로 하는 임상 단계의 생명공학 기업으로, 2025년 6월에 열리는 두 개의 투자자 컨퍼런스에 참여할 예정임을 발표했습니다. 회사는 2025년 6월 4일 오전 7시 35분(동부시간) 뉴욕에서 열리는 Jefferies Global Healthcare Conference에서 파이어사이드 채팅에 참여합니다. 또한 경영진은 2025년 6월 25일 오전 10시(동부시간) 뉴욕에서 개최되는 Oppenheimer Innovators in I&I Summit에서 "피부과: AA, HS, PSO"라는 제목의 패널 토론에 참석할 예정입니다. 웹캐스트와 다시보기는 회사의 투자자 관계 웹사이트에서 최소 30일간 이용할 수 있습니다.
Avalo Therapeutics (NASDAQ : AVTX), une société biotechnologique en phase clinique spécialisée dans les traitements des dysfonctionnements immunitaires, a annoncé sa participation à deux prochaines conférences pour investisseurs en juin 2025. La société participera à une discussion informelle lors de la Jefferies Global Healthcare Conference le 4 juin 2025 à 7h35 ET à New York. De plus, la direction prendra part à un panel intitulé « Dermatologie : AA, HS, PSO » lors du Oppenheimer Innovators in I&I Summit le 25 juin 2025 à 10h00 ET à New York. Les webcasts et rediffusions seront disponibles sur le site des relations investisseurs de la société pendant au moins 30 jours.
Avalo Therapeutics (NASDAQ: AVTX), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf Behandlungen bei Immunfehlregulation spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im Juni 2025 angekündigt. Das Unternehmen wird am 4. Juni 2025 um 7:35 Uhr ET in New York an einem Fireside-Chat auf der Jefferies Global Healthcare Conference teilnehmen. Außerdem wird das Management am 25. Juni 2025 um 10 Uhr ET in New York an einer Podiumsdiskussion mit dem Titel "Dermatologie: AA, HS, PSO" auf dem Oppenheimer Innovators in I&I Summit teilnehmen. Webcasts und Wiederholungen werden auf der Investor-Relations-Website des Unternehmens für mindestens 30 Tage verfügbar sein.
- None.
- None.
WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in June.
Jefferies Global Healthcare Conference 2025, New York
Fireside Chat
June 4, 2025, at 7:35 am ET
Oppenheimer Innovators in I&I Summit, New York
Panelist: “Dermatology: AA, HS, PSO”
June 25, 2025, at 10am ET
Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. For more information about Avalo, please visit www.avalotx.com.
About AVTX-009
AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology.
For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793
or
Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com
FAQ
What investor conferences will AVTX participate in during June 2025?
When is Avalo Therapeutics' presentation at the Jefferies Healthcare Conference 2025?
What is AVTX's role at the Oppenheimer Innovators Summit 2025?
Where can investors watch Avalo Therapeutics' conference presentations?
